Annexon Stock Fair Value Calculation – “ANNEXON’s Geographic Atrophy Candidate Fails in Phase 2 Trial, Stock Price Drops 20%”.
May 25, 2023
Trending News 🌧️
ANNEXON ($NASDAQ:ANNX), a biopharmaceutical company focused on developing novel treatments for rare and difficult-to-treat diseases, recently suffered a major setback in its clinical trial for a geographic atrophy candidate. The Phase 2 trial failed to meet its primary endpoint, resulting in a 20% decline in its stock price. The failure of the Phase 2 trial is a major blow to ANNEXON and its shareholders.
The company’s stock had been rising steadily before the news broke, but it has since dropped significantly. It remains to be seen how ANNEXON will respond to this setback and whether it can recover and continue to develop treatments for rare and difficult-to-treat diseases.
Analysis – Annexon Stock Fair Value Calculation
At GoodWhale, we have conducted a thorough analysis of ANNEXON‘s fundamentals. After our calculations, we believe that the fair value of ANNEXON’s stock is $8.0. This was determined using our proprietary Valuation Line. At the moment, ANNEXON’s stock is being traded at $5.2, which values it at 34.9% lower than its fair value. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Annexon. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -145.25 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Annexon. More…
| Operations | Investing | Financing |
| -119.01 | 9.71 | 140.47 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Annexon. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 268.78 | 53.92 | 4.05 |
Key Ratios Snapshot
Some of the financial key ratios for Annexon are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -42.4% | -35.2% |
Peers
The company’s lead product candidate, ANX005, is a monoclonal antibody that targets the C1q protein. The company is also developing ANX007, a monoclonal antibody that targets the C3 protein, for the treatment of autoimmune and inflammatory diseases.
– Larimar Therapeutics Inc ($NASDAQ:LRMR)
Larimar Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing new treatments for autoimmune and inflammatory diseases. The company has a market capitalization of 128.08 million as of 2022 and a return on equity of -73.95%. The company’s products are in various stages of development and have not yet been approved by the US Food and Drug Administration.
– DICE Therapeutics Inc ($NASDAQ:DICE)
DICE Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer. The company’s lead product candidate is DICE-945, a first-in-class, small molecule inhibitor of the PI3K/mTOR pathway. DICE-945 is currently being evaluated in a Phase I clinical trial in patients with advanced solid tumors.
– IO Biotech Inc ($NASDAQ:IOBT)
Asterias Biotherapeutics Inc is a biotechnology company. The Company is engaged in the development of regenerative medicine therapies based on pluripotent stem cells. The Company’s product candidates include AST-OPC1 (oligodendrocyte progenitor cells), AST-VAC2 (antigen-presenting autologous dendritic cells), and AST-VAC3 (folate receptor alpha-targeted dendritic cells).
Summary
Annexon, Inc. is an immunobiology company that develops therapies for neurodegenerative diseases. Recently, the company announced that a Phase 2 clinical trial for one of its geographic atrophy (GA) candidates failed to meet its primary endpoints. This news caused the stock price to drop by 20%, making it an unfavorable investment opportunity.
However, Annexon still has several other GA candidates in development, as well as a number of other potential therapies in its pipeline. Investors should conduct further research and pay attention to future developments before investing in the company. It’s also important to note that Annexon is not yet profitable, and there is no guarantee that its therapies will prove successful in the future.
Related Posts
Recent Posts
